New diabetes clinical trial: Semaglutide in Nonalcoholic Fatty Liver Disease

Published on: April 14, 2023 at 11:00AM
Condition:   Non-alcoholic Fatty Liver Disease
Interventions:   Drug: Rybelsus Oral Product;   Drug: Ozempic Injectable Product;   Drug: Tocopherol and/or Actos
Sponsor:   Zagazig University
Recruiting
https://ift.tt/p8VnT5e

Comments